The unexpected pleiotropic activities of RANTES

Journal of Immunology

Volumn 182, Issue 7, 2009, Pages 3945-3946

  Levy, Jay A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RANTES;

CHEMOTAXIS; DNA LIBRARY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; ANIMAL; IMMUNOLOGY;

ANIMALS; CHEMOKINE CCL5; HUMANS;

EID: 64249130618     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0990015     Document Type: Note

References (29)

1. Rossi, D., and A. Zlotnik. 2000. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18: 217-242.
2. Schall, T. J., J. Jongstra, B. J. Dyer, J. Jorgensen, C. Clayberger, M. M. Davis, and A. M. Krensky. 1988. A human T cell-specific molecule is a member of a new gene family. J. Immunol. 141: 1018-1025.
3. Appay, V., and S. L. Rowland-Jones. 2001. RANTES: a versatile and controversial chemokine. Trends Immunol. 22: 83-87.
4. Villalta, F., Y. Zhang, K. E. Bibb, J. C. Kappes, and M. F. Lima. 1998. The cysteine-cysteine family of chemokines RANTES, MIP-1α, and MIP-1β induce trypanocidal activity in human macrophages via nitric oxide. Infect. Immun. 66: 4690-4695. (Pubitemid 28453068)
5. Soria, G., and A. Ben-Baruch. 2008. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 267: 271-285.
6. Saenz-Lopez, P., R. Carretero, J. M. Cozar, J. M. Romero, J. Canton, J. R. Vilchez, M. Tallada, F. Garrido, and F. Ruiz-Cabello. 2008. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer 8: 382.
7. Cocchi, F., A. L. DeVico, A. Garzino-Demo, S. K. Arya, R. C. Gallo, and P. Lusso. 1995. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811-1815. (Pubitemid 3011045)
8. + cell anti-HIV factor (CAF). Trends Immunol. 24: 628-632.
9. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17: 657-700.
10. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane,Gprotein- coupled receptor. Science 272: 872-877. (Pubitemid 26154590)
11. Mackewicz, C. E., E. Barker, G. Greco, G. Reyes-Teran, and J. A. Levy. 1997. Do β-chemokines have clinical relevance in HIV infection? J. Clin. Invest. 100: 921-930. (Pubitemid 27371711)
12. Zanussi, S., M. D'Andrea, C. Simonelli, U. Tirelli, and P. De Paoli. 1996. Serum levels of RANTES and MIP-1α in HIV-positive long-term survivors and progressor patients. AIDS 10: 1431-1432. (Pubitemid 26333944)
13. McKenzie, S. W., G. Dallalio, M. North, P. Frame, and R. T. Means, Jr. 1996. Serum chemokine levels in patients with non-progressing HIV infection. AIDS 10: F29-F33.
14. Polo, S., F. Veglia, M. S. Malnati, C. Gobbi, P. Farci, R. Raiteri, A. Sinicco, and P. Lusso. 1999. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 13: 447-454.
15. 2+ signaling. Proc. Natl. Acad. Sci. USA 96: 14499-14504.
16. Ye, P., P. Kazanjian, S. L. Kunkel, and D. E. Kirschner. 2004. Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment. J. Lab. Clin. Med. 143: 310-319. (Pubitemid 38586496)
17. Schmidtmayerova, H., B. Sherry, and M. Bukrinsky. 1996. Chemokines and HIV replication. Nature 382: 767.
18. Kelly, M. D., H. M. Naif, S. L. Adams, A. L. Cunningham, and A. R. Lloyd. 1998. Cutting edge: dichotomous effects of β-chemokines on HIV replication in monocytes and monocyte-derived macrophages. J. Immunol. 160: 3091-3095.
19. + T cells: role of signal transduction. Proc. Natl. Acad. Sci. USA 95: 11880-11885.
20. Trkola, A., C. Gordon, J. Matthews, E. Maxwell, T. Ketas, L. Czaplewski, A. E. Proudfoot, and J. P. Moore. 1999. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. J. Virol. 73: 6370-6379. (Pubitemid 29327814)
21. Gordon, C. J., M. A. Muesing, A. E. I. Proudfoot, C. A. Power, J. P. Moore, and A. Trkola. 1999. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J. Virol. 73: 684-694.
22. Greco, G., S. H. Fujimura, D. V. Mourich, and J. A. Levy. 1999. Differential effects of human immunodeficiency virus isolates on β-chemokine and γ interferon production and on cell proliferation. J. Virol. 73: 1528-1534. (Pubitemid 29036808)
23. Liu, H., D. Chao, E. E. Nakayama, H. Taguchi, M. Goto, X. Xin, J. K. Takamatsu, H. Saito, Y. Ishikawa, T. Akaza, et al. 1999. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. USA 96: 4581-4585. (Pubitemid 29190379)
24. An, P., G. N. Nelson, L. Wang, S. Donfield, J. J. Goedert, J. Phair, D. Vlahov, S. Buchbinder, W. L. Farrar, W. Modi, et al. 2002. Modulating influence on HIV/AIDS by interacting RANTES gene variants. 99: 10002-10007.
25. Leonard, J. T., and K. Roy. 2006. The HIV entry inhibitors revisited. Curr. Med. Chem. 13: 911-934.
26. Vangelista, L., M. Secchi, and P. Lusso. 2008. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine 26: 3008-3015
27. Hütter, G., D. Nowak, M. Mossner, S. Ganepola, A. Müssig, K. Allers, T. Schnieder, J. Hofmann, C. Kucherer, O. Blau, et al. 2009. Long-term control of HIV by allogenic CCR5-δ 32/δ 32 stem cell transplantation. New Eng. J. Med. 360: 692-698.
28. Cohen, J. 2007. Building an HIV-proof immune system. Science 317: 612-614.
29. Glass, W. G., D. H. McDermott, J. K. Lim, S. Lekhong, S. F. Yu, W. A. Frank, J. Pape, R. C. Cheshier, and P. M. Murphy. 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203: 35-40. (Pubitemid 43139642)